Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Exxon Mobil Corporation — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Exxon Mobil Corporation trades at $177.94 (market cap $715.80B). The key difference: Exxon Mobil Corporation is far larger — about 95.2× Spyre Therapeutics Inc. Common Stock's market cap, and Exxon Mobil Corporation pays a 2.37% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Exxon Mobil Corporation for 100 Days on average.
| SYRE | XOM | |
|---|---|---|
Market Cap | $7.52B | $715.80B |
Volume | 1,441,031 | 11,362,664 |
Sector | Health | Energy |
52-Week High | $108.92 | $177.06 |
52-Week Low | $22.18 | $110.64 |
Typical Hold Time | 0 Days | 100 Days |
Enterprise Value | $6.52B | $747.58B |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
ExxonMobil (XOM) trades at $172.15, up 1.9% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Revenue declined to $323.91B in 2025 (SEC filing, 2025), though net income margin remains solid at 9.07%. Recent news highlights potential expansion into Venezuela's oil fields (Reuters, 2026-09-16) and operational updates in Guyana and Angola, supporting long-term growth targets.
The stock offers value with a P/E of 22.4 and strong cash flow, but faces headwinds from volatile oil prices and execution risks in new ventures. Analyst consensus is mixed with a $166.67 price target (MarketBeat, 2026-09-17), suggesting cautious optimism amid geopolitical and macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
